2023 annual financial data
CytoMed Therapeutics 2023 Operating margin
Direct answer
Operating margin was -310.17%.
Operating income was -1,579,150.5 SGD and net income was -4,144,214 SGD.
Operating cash flow was -3,540,867 SGD.
Get free CytoMed Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 509,125 SGD
- Operating income
- -1,579,150.5 SGD
- Net income
- -4,144,214 SGD
- Operating cash flow
- -3,540,867 SGD